A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based at the HudsonAlpha Institute of Biotechnology campus, announced in a press release this week that it will start clinical trials in the second half of this year. The funding comes from UK-based …